Scott J. Leischow, PhD, professor and director of the Clinical and Translational Science department at Arizona State University, discusses the current landscape of smoking cessation treatment and the importance of these treatments in the face of a pandemic featuring a virus that can cause short- and long-term respiratory distress. It's been approximately 10 years since a new pharmacologic treatment for smoking cessation has been approved by the FDA, but a Phase 3 study for cytisinicline, a drug with similar mechanisms of action to varenicline, but potentially "with a less problematic adverse event profile," is currently underway.